))
Digital Politics with Karen Jagoda is a non-partisan podcast featuring thought leaders and industry pioneers with insights about innovative approaches to political campaigns, voter engagement, mobilization, fundraising, persuasion, and GOTV. Topics include the power of mobile devices, leveraging social networks, message testing and targeting, cross-media advertising, grassroots organizing, and big data.
…
continue reading
Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.
…
continue reading
1
Voter Behavior in a Time of Political and Economic Uncertainty with Andrew Einhorn LevelFields
24:47
Andrew Einhorn, the Co-Founder and CEO of LevelFields, is an expert on fintech and AI. He highlights how political uncertainty and tight elections create market volatility and can impact voting behavior. Using their event intelligence platform, LevelFields connects the dots using AI to spot trends and predict future behavior. We talk about: How the…
…
continue reading
1
Strategies for Employers to Navigate the Complex Pharmaceutical Landscape with Dr. Mark Campbell RxBenefits TRANSCRIPT
Dr. Mark Campbell, Chief Pharmacy Officer at RxBenefits, a prescription benefit optimizer that works with self-funded employers to help them get the best clinical and economic value from their pharmacy benefit manager relationships. As the healthcare landscape has become more complex with the rise of specialty and high-cost drugs, a significant por…
…
continue reading
1
Strategies for Employers to Navigate the Complex Pharmaceutical Landscape with Dr. Mark Campbell RxBenefits
20:35
Dr. Mark Campbell, Chief Pharmacy Officer at RxBenefits, a prescription benefit optimizer that works with self-funded employers to help them get the best clinical and economic value from their pharmacy benefit manager relationships. As the healthcare landscape has become more complex with the rise of specialty and high-cost drugs, a significant por…
…
continue reading
1
AI-Powered Retinal Imaging Unlocks Biomarkers for Early-Stage Diseases with Dr. Vicky Demas identifeye HEALTH TRANSCRIPT
Dr. Vicky Demas, CEO of identifeye HEALTH, is using AI-powered diagnostic algorithms and automation to improve the accessibility and quality of retinal imaging, focusing on the early detection of diabetic retinopathy. The identifeye technology makes it easier for patients to get screened for eye conditions in primary care or retail settings. The go…
…
continue reading
1
AI-Powered Retinal Imaging Unlocks Biomarkers for Early-Stage Diseases with Dr. Vicky Demas identifeye HEALTH
19:28
Dr. Vicky Demas, CEO of identifeye HEALTH, is using AI-powered diagnostic algorithms and automation to improve the accessibility and quality of retinal imaging, focusing on the early detection of diabetic retinopathy. The identifeye technology makes it easier for patients to get screened for eye conditions in primary care or retail settings. The go…
…
continue reading
1
Raising Awareness About Safe Practices and Opportunities for IV Therapy with Felicia Janovich American IV Association TRANSCRIPT
Felicia Janovich is a founding member of the American IV Association, which advocates for safe and effective IV therapies, including hydration, vitamin infusions, and treatments to support patients with chronic conditions or undergoing chemotherapy. While there is limited research on the effectiveness of these IV therapies, AIVA is working to colle…
…
continue reading
1
Raising Awareness About Safe Practices and Opportunities for IV Therapy with Felicia Janovich American IV Association
20:29
Felicia Janovich is a founding member of the American IV Association, which advocates for safe and effective IV therapies, including hydration, vitamin infusions, and treatments to support patients with chronic conditions or undergoing chemotherapy. While there is limited research on the effectiveness of these IV therapies, AIVA is working to colle…
…
continue reading
1
Tolerable Oral Alzheimer’s Medication to Manage Symptoms Slow Progression with Michael McFadden Alpha Cognition TRANSCRIPT
Michael McFadden is the CEO of Alpha Cognition, a biopharmaceutical company focused on developing treatments for brain diseases such as Alzheimer's, ALS, and traumatic brain injury. Their drug ZUNVEYL, recently approved by the FDA, is an oral treatment for mild to moderate Alzheimer's that improves symptoms such as memory loss, mental processing sp…
…
continue reading
1
Tolerable Oral Alzheimer’s Medication to Manage Symptoms Slow Progression with Michael McFadden Alpha Cognition
19:02
Michael McFadden is the CEO of Alpha Cognition, a biopharmaceutical company focused on developing treatments for brain diseases such as Alzheimer's, ALS, and traumatic brain injury. Their drug ZUNVEYL, recently approved by the FDA, is an oral treatment for mild to moderate Alzheimer's that improves symptoms such as memory loss, mental processing sp…
…
continue reading
1
Robust Cybersecurity Risk Management in the Healthcare Ecosystem with George Pappas Intraprise Health TRANSCRIPT
George Pappas, CEO of Intraprise Health, works with various healthcare organizations across the healthcare industry and healthcare ecosystem to help address cybersecurity risks. While recent cyber attacks have raised awareness about the need for better cybersecurity measures, the complexity of healthcare IT systems creates significant challenges fo…
…
continue reading
1
Robust Cybersecurity Risk Management in the Healthcare Ecosystem with George Pappas Intraprise Health
18:27
George Pappas, CEO of Intraprise Health, works with various healthcare organizations across the healthcare industry and healthcare ecosystem to help address cybersecurity risks. While recent cyber attacks have raised awareness about the need for better cybersecurity measures, the complexity of healthcare IT systems creates significant challenges fo…
…
continue reading
1
Developing Non-Opioid Pain Medication with Reduced Abuse Potential with Ketan Mehta Tris Pharma TRANSCRIPT
Ketan Mehta, Founder and CEO of Tris Pharma, is focused on developing non-addictive pain medication. Their lead drug candidate is designed to be an effective pain drug without the respiratory-depressive and addictive side effects of traditional opioid drugs. This drug works by targeting the nociceptin receptor and has also shown promise to help cur…
…
continue reading
1
Developing Non-Opioid Pain Medication with Reduced Abuse Potential with Ketan Mehta Tris Pharma
18:53
Ketan Mehta, Founder and CEO of Tris Pharma, is focused on developing non-addictive pain medication. Their lead drug candidate is designed to be an effective pain drug without the respiratory-depressive and addictive side effects of traditional opioid drugs. This drug works by targeting the nociceptin receptor and has also shown promise to help cur…
…
continue reading
Beth Houck, Chief Executive Officer at SonarMD, works with payers and physician practices to provide proactive, value-based care for patients with chronic GI conditions. They use a digital platform to monitor self-reported patient symptoms and enable physicians to identify those patients that need attention. This approach aims to improve patient ou…
…
continue reading
Beth Houck, Chief Executive Officer at SonarMD, works with payers and physician practices to provide proactive, value-based care for patients with chronic GI conditions. They use a digital platform to monitor self-reported patient symptoms and enable physicians to identify those patients that need attention. This approach aims to improve patient ou…
…
continue reading
1
How Generative AI is Unlocking Insights to Expand Drug Development with Dr. Chris Bouton Certara TRANSCRIPT
Dr. Chris Bouton, the Senior VP and Head of Artificial Intelligence at Certara, is exploring applying generative AI to drug discovery and development to improve efficiency and identify novel therapeutics across various use cases. The focus is on developing specialized secure AI models to integrate internal data with the Certara platform. Generative…
…
continue reading
1
How Generative AI is Unlocking Insights to Expand Drug Development with Dr. Chris Bouton Certara
19:27
Dr. Chris Bouton, the Senior VP and Head of Artificial Intelligence at Certara, is exploring applying generative AI to drug discovery and development to improve efficiency and identify novel therapeutics across various use cases. The focus is on developing specialized secure AI models to integrate internal data with the Certara platform. Generative…
…
continue reading
1
Unique Fat-Inhibiting Approach Targets Multiple Pathways in Metabolic Liver Disease with David Happel Sagimet Biosciences TRANSCRIPT
David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, th…
…
continue reading
1
Unique Fat-Inhibiting Approach Targets Multiple Pathways in Metabolic Liver Disease with David Happel Sagimet Biosciences
24:15
David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, th…
…
continue reading
1
Untangling the Complexity of the 340B Drug Discount and Medicaid Drug Rebate Programs with Dr. Gavin Magaha Kalderos TRANSCRIPT
Dr. Gavin Magaha, Senior Director for External Affairs and Policy at Kalderos, describes the 340B drug discount program created in 1992 to help safety net healthcare providers obtain discounted drugs. Over time, this program has grown in complexity, and issues have arisen around duplicate discounts where Medicaid rebates are involved. The current 3…
…
continue reading
1
Untangling the Complexity of the 340B Drug Discount and Medicaid Drug Rebate Programs with Dr. Gavin Magaha Kalderos
19:05
Dr. Gavin Magaha, Senior Director for External Affairs and Policy at Kalderos, describes the 340B drug discount program created in 1992 to help safety net healthcare providers obtain discounted drugs. Over time, this program has grown in complexity, and issues have arisen around duplicate discounts where Medicaid rebates are involved. The current 3…
…
continue reading
1
Using AI Big Data to Engineer More Efficient Drugs to Treat Rare and Common Diseases with Chris Hart Creyon Bio TRANSCRIPT
Chris Hart, Co-Founder, CEO, and President of Creyon Bio, is focused on engineering drugs rather than just discovering them through serendipity and traditional methods. Creyon is developing oligonucleotide medicines for rare and common diseases by applying AI and big data models of the molecular and genetic basis of diseases to develop safe and eff…
…
continue reading
1
Using AI Big Data to Engineer More Efficient Drugs to Treat Rare and Common Diseases with Chris Hart Creyon Bio
20:51
Chris Hart, Co-Founder, CEO, and President of Creyon Bio, is focused on engineering drugs rather than just discovering them through serendipity and traditional methods. Creyon is developing oligonucleotide medicines for rare and common diseases by applying AI and big data models of the molecular and genetic basis of diseases to develop safe and eff…
…
continue reading
1
Palatable Elemental Diet Changes Management Options for GI Patients with Krystyna Houser mBIOTA Labs TRANSCRIPT
Krystyna Houser is the Founder of mBIOTA Labs, a company that develops effective and tolerable elemental diets and medical foods for treating gastrointestinal disorders such as IBS, IBD, SIBO, IMO, and Crohn's disease. While short-term liquid elemental diets have been used in the past to treat GI conditions, the formulation has been very unpalatabl…
…
continue reading
1
Palatable Elemental Diet Changes Management Options for GI Patients with Krystyna Houser mBIOTA Labs
15:23
Krystyna Houser is the Founder of mBIOTA Labs, a company that develops effective and tolerable elemental diets and medical foods for treating gastrointestinal disorders such as IBS, IBD, SIBO, IMO, and Crohn's disease. While short-term liquid elemental diets have been used in the past to treat GI conditions, the formulation has been very unpalatabl…
…
continue reading
